Video Transcription
Jerry Chang 00:00
A company named FaceHeart. We look at your face. We know your heart; it's as simple as that. So how do we do that? As easy as using your magic, which is your cell phone. Look at your selfie. Look at yourself for about one minute, then we reach your vital signs. In terms of vital signs, we have basically four: the heart rate, blood pressure, oxygen saturation, and respiration rate. How does that happen? This is pretty much the only technical slide I'm going to share with you. We take 30 pictures every second of your face, and we grab the rectangular part underneath your eyes and above your lips. We compare the red color changes underneath your face, just like looking at a movie. So, red color changes when the heart pumps; the black goes up and suddenly becomes more red. It goes up, so then you become more light. This is the heart rate. So essentially, we recreate the frequency wave we call RPPG. PPG is Apple Watch; R means remote. So it doesn't matter if it's PPG or RPPG, we all compare it with ECG, which is the medical device. I was in venture capital in this industry for 10 years. We always say software is only one thing: simple is beautiful. So simple as it is, it's beautiful. The product has to be straightforward. So I'm going to share some of the 'S's that we use as venture capitalists. The next one, we say software is simple; simple is beautiful. But what is going to be next? The next 'S' is really what we call systematic integration. You look at what you have today; you're going to position your product as long as you're going to integrate it. After that, basically, your business model is revealed. We do B2B focus; we don't do B2C. We can leverage all the system integrators. They do licenses. We do one-time licenses. We do recurring revenues, pretty much per scan or subscription share basis. So these are the things in order to do flexible integrations. We basically have edge computing. Everything runs on your cell phone; there's no connection to the network, all the necessary. But 85% of our customer perspective are using edge devices. Some of our customers will elect to use the cloud. So we do have a cloud solution with support. You can see the Android, iOS, Windows, and all the popular development platforms. That's what we call the second 'S': simple, systematic integrations. The million-dollar question is how accurate can it be? How about we got FDA approval? We got it in September last year for our first vital, the 510(k). The K number is K223622. If you are really interested, you can look up what's happening with the magic. Go to the website, tap FDA K2236, and looking at the summary sections, which is hyperlinked; it will give you about 20 pages of PDF, whatever you want to know about the trick of this whole thing. It's all been written and verified by the FDA. How can it happen? It happens because we have, in the past four years, thanks and no thanks to the pandemic, had no way to go. We conducted more than 18 IRBs; six are closed, and the others are ongoing. Collectively, we have over 6000 testers. We collected 200 meaningful image datasets. That's how we achieve this so-called accuracy; the heart rate being approved by the FDA is plus or minus three BPM. This one will have to account for all the skin color types, from one to six, with glasses, beards, mustaches, females with makeup, whatever you can think of, the lux, the light coming from all the places, and also the temperature, so-called color temperature. Everything has to be considered. We fully expect to get the respiration rate cleared by the end of this year from the FDA. We are in the very final process of getting the respiration rate, which is plus or minus two breaths per minute; that's the requirement from the FDA. This one, we are doing the De Novo. These two are the 510(k) for blood pressure and oxygen saturation. It's a De Novo; it's actually exactly what the FDA wanted. The increase in oxygen saturation from 2.8% to 3.5% is because they want to measure 70. My friend, 70 people are dying before age 19; it's at 2.8%. In order to do that, they don't want sick people; they don't want you to put drugs in there to induce the 70. So we had to go to the peak in Colorado, in the Rocky Mountains, to get a consensus on the 70s oxygen saturation; that is how much you work with. This is the next 'S' we call significant innovations. By doing this, we build sustainable leading edges; that's what this company is here to build. We had no revenue until March. We said, let's go to the market after four and a half years of doing nothing. Your strategy is really the very last 'S' that a lot of people put first; it's called strategy. If you don't have the previous 'S's, you don't have a strategy. Strategy, we do. You can see it's four different market segments: smart health care, all medical requests, you know, require telemedicine, telehealth. People talk a lot; we should have insurance providers use it as underwriting screening just to renew the subscription to see if you're healthy enough. Certainly, there's mobile health, fitness, wellness programs that do not require marketing; it's a new way for people to do digital health and track their records. So in the middle part are all the solutions or products. You can rank it for remote patient monitoring. We talk about the US market; you talk about CMS reimbursement coding: 99 453, 454-450-7458, whatever you want. That's the remote patient monitor. We integrate with the EHR through Epic, through Microsoft 5. It's all integration: telehealth, telemedicine. We support digital TV. We support robots. We certainly fully integrate into Zoom on an attachment we call the Lucy couple. You don't want to feel into it. We also do Microsoft meetings, some pharmaceutical companies doing DCT, decentralized, centralized clinical trials because the vaccine for COVID skipped phase three, sometimes skipped phase two. So they require a lot of RWD. Certainly, the revenue before we got old, if they're clear, is coming from the winners program because it is the market; all the money is there. If it's not for investors, this is my last slide, but since it's for investments, I use some competitors, and so with bean.ai is a real company. It's a new logic; it's in Canada. So you can go to their website and look for that. We certainly will say we are better than every one of them. We do; we get a lot of customers converting from them to us. They have their show folder. If you want to be interested, I can share my insights with you. This is the roadmap. People ask, what's your product roadmap? Every time you asked me this question two years ago, I said we don't have a roadmap. The reason is I didn't even get my first roadmap down, which is the heart rate. So where the roadmap is very easy: we got FDA approval, we go for CE mark, we go to HSA with Singapore for Southeast Asia, exactly the same orders. We're going to get heart rate and respiration rate. These two, we have to do a pre-submission, and we do a De Novo. We're dancing with the wolf, which is the FDA. Nobody knows what's happening, but it's happening now. We hope we can get it. We have atrial fibrillation; we're going to file next week; we boast 92% accuracy. This is the four years started with the hospitals on that, so this is the so-called medical clearance roadmap for us. People ask a lot; people want revenue. As I said, we start to step in on March 1 this year; we don't have that much revenue, which we don't care about because it's a startup. The whole revenue forecast is a running calculation. You will see when I get all these things cleared, the situation will change a lot. But investors want to see whatever we can show as it is today. So we actually, luckily, our research was granted from the Taiwanese government. But unfortunately, we hate the pandemics. Originally, we were embedded solutions going into medical devices. The pandemic forced us to switch to getting all the clean FDA certifications. So we're fortunate to also get a $7 million plus mass investment. We are in what is called a plus run or B run or whatever. All the money we're trying to raise up to ten million is going to be donated to FDA for CE mark. Everything else is for the clinical trial, but that's life. That's life when you are in the digital health market today. So Dr. Wu and Dr. Chu, the co-founders, in the middle, are the fat, chubby guys. Me, we have about 50 plus PIs and co-PIs as our advisors. You try; if you like it, you can scan the rightmost QR code. You can use your browsers and go home and try as many times as you want; it's a closed cloud solution put on AWS. Enjoy your healthy life. My name is Jerry. I'm from FaceHeart. Thank you.
